Abbott shares fall around 4.5% as Nutrition business spin-off pressures stock

Traders Union
All News
Stocks
Abbott Laboratories slides 4.46% today

Highlights

Abbott will spin off its global Nutrition business into a separate public company by the end of 2027 with a tax-free distribution for shareholders.
Third quarter 2026 results showed sales grew 14.5% to $13.01 billion and earnings per share matched analyst expectations at $1.42.
Shares of Abbott trade below key moving averages with technical indicators giving mixed signals and a forecast range of $95.33 to $100.71 in the next week.

Tax-free spin-off and dividend pledge fail to counter persistent selling

Abbott announced that it will separate its global Nutrition business into a new independent, publicly traded company, with the transaction targeted to close by the end of 2027. The company stated the distribution will be tax-free for existing shareholders, and both Abbott and the new Nutrition company are expected to maintain a combined dividend equal to Abbott's current payout at the time of the split. For the third quarter of 2026, Abbott reported sales of $13.01 billion, a 14.5% increase, and earnings per share of $1.42 that met consensus estimates, with its 411th consecutive quarterly dividend having been declared, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, views Abbott’s technical configuration as weak after the recent spin-off announcement. He notes the price falling below critical moving averages and sees muted reaction despite the news. The ongoing divergence between mixed momentum indicators and persistent downside signals caution. Dividend continuity does little to reassure short-term investors, given prevailing selling. "Investors should remain defensive until Abbott reclaims the $100.71 level on convincing volume," says Kharitonov.

Viktoras Karapetjanc, expert at Traders Union, points to Abbott’s strategic move as a catalyst for long-term value creation. He highlights continued revenue growth, resilient dividends, and a bullish structure above $95.33. The planned split boosts management focus, unlocking new investment opportunities. Karapetjanc adds, "I expect the market to recognize Abbott’s underlying strength — further growth remains likely as the spin-off approaches."

Sholanke Dele, market strategist, notes persistent selling pressure despite recent news. He sees investor sentiment as fragile, with price action suggesting little confidence post-announcement. Dele cautions, "Until volatility subsides and the downside risk narrows, I would not expect a sustained rebound in Abbott shares."

Mixed momentum signals emerge as price stays below major averages

Abbott is trading below its 20-day, 50-day, and 200-day moving averages at $100.98, $105.68, and $102.59 respectively, reflecting ongoing pressure from sellers across short-, medium-, and long-term trends. The nearest ceiling is the Ichimoku Kijun at $100.57, with near-term support at $95.33. The alignment of the 50-day average above the 200-day signals a still-bullish long-term structure. Momentum signals are mixed: MACD is neutral, ADX indicates waning trend strength with a sell forecast, RSI is near mid-range with a buy signal, the Stochastic RSI is neutral, and CCI has a buy bias. Bull/Bear Power remains above zero but in overbought territory, while the Awesome Oscillator supports the recent upside bias. The stock opened lower and is trading near the session’s low, with intraday volatility at 5.10%.

Earlier, analysts noted that mixed technical readings and ongoing volatility kept Abbott shares in a cautious holding pattern, with traders closely monitoring for a clear breakout or breakdown. The current article adds a new dimension by highlighting the Nutrition business spin-off and persistent downside momentum, indicating that a break below $95.33 could now trigger further risk in the near term.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.